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Abstract 
Bacterial endotoxins have high immunogenicity. Phage biology studies as well as therapeutic 
phage applications necessitate highly purified phage particles. In this study, we compared 
combinations of seven different endotoxin removal strategies and validated their endotoxin 
removal efficacy for five different phages (i.e. four Pseudomonas aeruginosa phages and one 
Staphylococcus aureus phage). These purification strategies included Endotrap HD column 
purification and/or CsCl density centrifugation in combination with Endotrap purification, 
followed by organic solvent (1-octanol), detergent (Triton X-100), enzymatic inactivation of 
the endotoxin using alkaline phosphatase and CIM monolytic anion exchange 
chromatography. We show that CsCl density purification of the P. aeruginosa phages, at an 
initial concentration of 1012 - 1013 pfu/ml, led to the strongest reduction of endotoxins, with 
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an endotoxin removal efficacy of up to 99 %, whereas additional purification methods did 
not result in a complete removal of endotoxins from the phage preparations and only 
yielded an additional endotoxin removal efficacy of 23 to 99 %, sometimes accompanied 
with strong losses in phage titer. 
 
Keywords 
Endotoxins, lipopolysaccharides (LPS), Bacteriophages, Pseudomonas aeruginosa, 
Staphylococcus aureus, Endotoxin removal, Endotoxin quantification. 
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1. Introduction 
The purification of bacteriophage particles is important for two reasons: either to 
investigate the phage particle on its own (i.e. phage biology studies) or for 
therapeutic application of phages, which is currently undergoing a resurgence (Adhya 
et al., 2014; Krystyna Dabrowska et al., 2014; Ly-Chatain, 2014; Miedzybrodzki et al., 
2012; Thiel, 2004; Vandenheuvel et al., 2015). When phages are propagated on 
Gram-negative bacterial hosts, endotoxins or lipopolysaccharides (LPS) have to be 
removed from these preparations. Endotoxins are part of the Gram-negative 
bacterial outer membranes and play an important role in the organization and 
stability of the bacterial cell (Ki et al., 1994). Bacterial endotoxins are well known for 
their immunogenic, pro-inflammatory and pyrogenic effects (Aderem and Ulevitch, 
2000). In conditions where the body is exposed to endotoxins excessively or 
systemically, a systemic inflammatory reaction can occur, leading to multiple 
pathophysiological effects such as endotoxin shock, tissue injury and death (Anspach, 
2001; Erridge et al., 2002; Ogikubo et al., 2004). Therefore, when phages are 
prepared for therapeutic purposes, it is crucial that different bacterial contaminants 
are removed which affect the efficacy and safety of the administration during phage 
therapy. The maximal level of endotoxins for intravenous applications of 
pharmaceutical and biological products is set at 5 endotoxin units (EU), i.e. 500 pg of 
endotoxins10, per kg of body weight per hour (Daneshian et al., 2006). Additionally, 
bacterial endotoxins may also interfere with phage biology studies, especially when 
trying to establish the interaction of phages with the immune system. 
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Several strategies have been described for the removal of endotoxins from phage 
preparations. Here we compared different endotoxin removal strategies for the 
removal of endotoxins from five phages, i.e. four Gram-negative Pseudomonas 
aeruginosa phages and one Gram-positive Staphylococcus aureus phage (Table 1). 
The S. aureus phage forms a negative control for the endotoxin determination assay, 
as this phage is grown on a Gram-positive host which produces no endotoxins. 
Strategies were compared, taking into account the efficacy in removing endotoxins in 
relation to their effect on the phage titer yield.  
 
2. Results and discussion 
In this study, we evaluated the endotoxin removal efficacy of seven purification 
strategies (Figure 1). To determine which strategy has the best endotoxin removal 
capacity, in combination with the minimal amount of phage loss, we calculated the 
‘endotoxin removal efficacy’, defined as the ratio of the endotoxin units (EU) per 
plaque forming unit (pfu) multiplied by the phage recovery of the purified sample and 
the original sample subtracted from one (Table 2). The endotoxin quantification by 
Endozyme was validated by endotoxin quantification by means of Endosafe-PTS, for a 
selected number of samples. Both detection methods gave similar results within the 
same order of magnitude (Table S1)  
The endotoxin removal strategies include either (1) Endotrap HD column purification 
alone (Merabishvili et al., 2009) (φET), or (2) CsCl density gradient ultracentrifugation 
alone (Lavigne et al., 2009) (φC) or (3) followed with Endotrap HD purification (φCET), 
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and φET or φCET followed by either (4) organic solvent (1-octanol; Szermer-Olearnik 
and Boratyński, 2015) treatment (OS), (5) detergent Triton X-100; Marcus and Prusky, 
1987; Petsch and Anspach, 2000) treatment (TX), (6) enzymatic inactivation of the 
endotoxin using alkaline phosphatase (Bentala et al., 2002) (AP) or (7) anion-
exchange chromatography (CIM DEAE disk column (CIM); Adriaenssens et al., 2012). 
We opted for these combined strategies, to compare the efficacy of purifying raw 
phage lysates (φET) versus CsCl-purified phages (φCET). As expected, phage ISP 
preparations from a Gram-positive host did not show any detectable endotoxin levels 
before or after any of the purification strategies (Table S1). The four P. aeruginosa 
phages contained between 326,000 and 7,465,000 EU/ml (Table S1). This 
concentration was measured after purification of phage lysates with Endotrap HD 
and therefore may initially be higher. However, it is possible that these values 
correspond largely to the initial order of magnitude of the endotoxins present in the 
crude phage preparations, because the removal efficacy of the Endotrap HD 
purification, starting from the CsCl purified phages, was only between 63.09 – 
94.56 % (Table 2). Cooper et al. (2014) showed that crude P. aeruginosa phage 
preparations contained more than 105 EU/ml, which was in correspondence with our 
quantification of preparations that were purified only once with Endotrap HD. Dufour 
et al. (2016) recently described that three to five consecutive rounds of Endotrap HD-
based endotoxin removal, starting from CsCl purified phages, led to a further 
reduction of the endotoxin concentration to below 0.5 EU/ml, but this is a time-
consuming strategy with a variable and phage-dependent outcome. 
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2.1. Organic Solvent (OS) 
The organic solvent extraction was described by Szermer-Olearnik and Boratyński 
(2015) and is based on the principle that endotoxins partition favorably in the organic 
phase, while the molecules of interest (in our case phages) are retained in the 
aqueous phase. Our results show that the organic solvent strategy has an endotoxin 
removal efficacy between 63.83 and 99.98 % for φET and between 23.40 and 63.36 % 
for the φCET samples. The only exception is P. aeruginosa phage LUZ19 where there 
was an enrichment of endotoxins after the 1-octanol treatment, i.e. an endotoxin 
removal efficacy of -16.55 %. This enrichment could be explained by a potential 
release of endotoxins bound to the phage particle, which when bound are not 
detectable in the endotoxin detection assay.  
The organic solvent strategy led to strongest reduction of endotoxins in the P. 
aeruginosa phage PNM φET and phage LUZ19 φET preparations, with an endotoxin 
removal efficacy of 99.98 and 99.68 % respectively. This was only accompanied with a 
reduction of the P. aeruginosa phage PNM with two orders of magnitude. For both 
phages, a strong reduction in phage titer of up to five orders of magnitude difference 
was observed.  
 
2.2. Detergent: Triton X-100 
The endotoxin removal strategy using detergents such as Triton X-100 has been well-
established. According to Petsch and Anspach (2000), endotoxins can be removed 
using a two-phase extraction, employing detergents such as those of the Triton series. 
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An endotoxin removal efficacy of up to 93.21 % and 99.96 % could be observed for 
the φET and φCET phage samples, respectively (Table 2). The use of activated 
charcoal for the removal of Triton X-100 led to a reduction in the endotoxin 
concentration after three consecutive rounds. Around 6.29 – 7.14 % endotoxins 
remained for the φET preparations and between 0.31 – 43.6 % endotoxins remained 
for the φCET preparations. However, the activated carbon was not able to remove all 
of the Triton X-100. This became apparent when the samples became viscous when 
stored at 4 °C for prolonged time. The phage recovery for the φET was between 0.07 
– 17.20 % and for the φCET it was between 1.80 – 52.22 % (Table 3), indicating that 
the Triton X-100 strategy has an effect on the phage activity. 
 
2.3. Enzymatic inactivation of endotoxins: alkaline phosphatase 
An alternative method for the removal of endotoxins is enzymatic inactivation of 
endotoxins by the removal of the phosphate group of the lipid A fraction by means of 
alkaline phosphatase (Bentala et al., 2002). Consequently, the treated endotoxin 
becomes immunologically inactive and should not be detected in a classical Limulus 
Amebocyte Lysate (LAL) assay or by recombinant factor C (rFC) assays as used in this 
study. However, the treatment of the φET and φCET phage preparations with alkaline 
phosphatase had very low endotoxin removal efficacies (i.e. lower then 20 %; Table 2) 
and did not lead to a reduction in the endotoxin concentration (Table S1). In addition 
this method had a negative impact on the number of infectious phage, dropping 2 – 4 
orders of magnitude (Table 3). 
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Although this strategy has been described for the inactivation of purified endotoxins, 
when it was applied on phage samples there was no reduction in the endotoxin 
concentration. This might indicate that the phages either inhibit the enzymatic 
activity of the alkaline phosphatase or that the phages, through the binding of the 
endotoxins, hide the phosphate groups on the lipid A part. Consequently, this can 
result in the endotoxins not being completely inactivated by the enzyme while still 
being detectable in the endotoxin detection assay. 
 
2.4. Anion-exchange purification: CIM DEAE disks 
The final strategy that was evaluated was the anion-exchange purification using CIM 
DEAE columns. This technique was previously described for its application in the 
purification and concentration of phages (Adriaenssens et al., 2012), but the authors 
did not evaluate the endotoxin removal potential. In this strategy, the phages are 
retained on the column through ionic interaction. This purification protocol was only 
performed for the φET preparations of P. aeruginosa phages PNM and LUZ19. 
Although the two phages that were purified by this method (i.e. P. aeruginosa phage 
PNM and LUZ19) have a high sequence similarity, the endotoxin removal efficacy 
varied between these two phages (i.e. 98.15 and 40.39 %, respectively; Table 2). A 
strong reduction in phage titers from 1013 to 1011 pfu/ml for both the P. aeruginosa 
phages PNM and LUZ19 was observed (Table 3). The limited reduction in endotoxin 
concentration after the anion-exchange purification could be explained by the fact 
that endotoxins also have the ability to interact with anion-exchange columns. 
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According to Hou and Zaniewski (1990), the capacity of endotoxin removal by anion-
exchange matrices through charge interaction depends on the number of available 
positively charged groups existing in the matrices. They observed a maximum 
adsorption of endotoxins at pH 6.8 when DEAE columns were used, and at pH 8.0 
when QA columns were used. They also found that the endotoxin adsorption was 
found to be unaffected at up to 0.2 M salt concentration (Hou and Zaniewski, 1990). 
We found that both phages were retained at the column at a pH of 7.5 and eluted at 
a NaCl concentration above 0.6 M. Therefore, the removal of endotoxins without 
loosening the phages from the column is cumbersome. Hence, the endotoxins co-
elute with the phages minimizing the ability to obtain endotoxin free phage 
preparations. The reduction in phage titers results from the phage binding capacity of 
the columns, which is phage-dependent. 
 
3. Conclusions 
Starting from between 2.5 x 1012 and 8 x 1013 pfu/ml of 4 different P. aeruginosa 
phages (Table 3), contaminated by 31,020 and 7,465,000 EU/ml (Table S1), we found 
that CsCl density gradient ultracentrifugation established an endotoxin removal 
efficacy between 18.42 and 99.68 % (Table 2) while reducing the number of phages 
with maximum two orders of magnitude (Table 3). Further endotoxin removal of 
these CsCl preparations with endotrap, OS, TX, AP or CIM did reduce endotoxins 
further with a maximum endotoxin removal efficacy of 99.9 %, whereas several of 
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these additional treatments were detrimental for the phage titer, which was even 
reduced to 0.0004 % for the P. aeruginosa phage PNM φCET OS treated sample. 
From our comparative study, it becomes clear that it is hard to achieve complete 
removal (i.e. ≥ 99.99 %) of endotoxins from a phage sample. For therapeutic purposes, 
only 5 EU/ml/kg/h can be present in the samples for intravenous applications 
(Daneshian et al., 2006). We clearly find that the removal of large volumes of 
endotoxins is easier than the removal of small residual endotoxins, as the endotoxin 
removal efficacy of the different procedures starting from the phage lysate (φET) 
preparation is much higher than those form the CsCl purified (φCET) preparations 
(Table 2). Unfortunately, we were not able to obtain an universal strategy that could 
be used for the removal of endotoxins from any given phage preparation. Therefore, 
each phage needs to be evaluated individually for the optimal strategy for the 
removal of endotoxins, taking into account the potential drop in phage titers. The 
CsCl purification (φC) seems to have the highest efficacy in removing endotoxins. 
Although this technique might not be suitable for all applications such as phage 
therapy where high throughput and up scaling is a must, this strategy might be 
important for phage biology studies in which endotoxin contamination may result in 
confounding effects.  
Since the phage titers used for phage therapy are usually around 108 pfu/ml 
(Merabishvili et al., 2009), the phage preparations can be further diluted leading to a 
further drop of the endotoxin concentration (ranging from 0.0002 to 316 EU/ml for 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
11 
 
108 pfu/ml phage preparations; Figure 2) and subsequent safe use. Therefore, labor 
intensive endotoxin removal strategies should not be necessary for therapeutic 
phage preparations, knowing that the dilution of high titer phage preparations would 
be sufficient. Unfortunately, dilution of the phage preparations is not always possible 
when performing phage biology studies such as evaluating the immunological 
properties of phages on the mammalian immune system, where high phage titers 
might be advised (Biswas et al., 2002; Miernikiewicz et al., 2013). 
Although this study has as a limitation that no technical replicates were obtained for 
the different endotoxin removal strategies, our results do indicate that the endotoxin 
removal is phage dependent, and thus needs to be evaluated individually for each 
phage. To obtain a complete removal of endotoxins, a combination of strategies 
could be used, such as treating the phage lysate with Triton X-100 followed by a 
purification and concentration of the phages through means of anion-exchange (i.e. 
DEAE disks) or by using consecutive rounds of Endotrap HD endotoxin removal after 
CsCl density centrifugation, as suggested by Dufour et al. (2016). 
4. Material and methods 
4.1. Bacteriophage and bacteria 
4.1.1. Phage propagation 
Bacteriophage stocks (Table 1) were prepared using the double-agar overlay method 
as described in Merabishvili et al. (2009) (Merabishvili et al., 2009). Briefly, one ml of 
the phage preparation containing 106 plaque forming units (pfu) of bacteriophages 
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was mixed with 3 ml of molten (45 °C) Lysogeny Broth (LB) (Becton Dickinson, 
Erembodegem, Belgium) top Bacto agar (0.6 %) (Becton Dickinson) and 100 µl of the 
host strain suspension (end concentration of 107 cfu/ml) in a sterile 14 ml tube 
(Falcon, Becton Dickinson). This mixture was plated onto freshly made 90 mm 
diameter Petri dishes (Plastiques Gosselin, Menen, Belgium), filled with a bottom 
layer (20 ml) of 1.5 % LB agar, and incubated aerobically at 32 °C for 16 h. 
Subsequently, 200 µl of chloroform was added to the lids of the Petri dishes and the 
inverted plates were further incubated at 4 °C for 1 h. The top layer of the double-
agar layer was scraped off using a sterile Drigalski spatulum and transferred to a 
sterile 14 ml tube. 
The harvested phages were centrifuged for 20 min at 6,000 x g at 4 °C. The 
supernatant was aspirated using a sterile 10 ml syringe (BD Plastipak, Becton 
Dickinson) with a 30 G sterile needle (BD Microlance 3, Becton Dickinson) and passed 
through a 0.22 µm membrane filter (Sartorius Stedim, Zellik, Belgium). The filtrate 
was subsequently centrifuged at 35,000 x g for one hour. The phage pellet was 
resuspended in 5 ml saline and stored at 4 °C overnight before determining the phage 
titer. Preferably, the titer of the phage lysate should be checked at least one day later 
according to the above described procedures. This will allow phage particles that may 
have clumped together during centrifugation steps to disengage (Kutter and 
Sulakvelidze, 2004). 
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4.1.2. Phage titer determination 
The bacteriophage titer was determined by assaying decinormal serial dilutions 
(log(0) to log(-12)) of the bacteriophage suspension with the overlay method 
(Merabishvili et al., 2009). One ml of each dilution was mixed with 3 ml of molten 
(45 °C) LB 0.6 % top Bacto agar and the host strain (end concentration of 107 cfu/ml) 
in a sterile 14 ml tube. This mixture was plated in triplicate onto 90 mm diameter 
Petri dishes, filled with a bottom layer of 1.5 % LB agar, and incubated for 16 h at 
37 °C. To determine the original bacteriophage concentration, plates with one to 100 
distinguishable homogenous plaques were counted. The mean was then calculated 
for the triplicate plates. 
4.2. Endotoxin removal strategies 
All manipulations were carried out using endotoxin-free reagents. Figure 1 gives a 
schematic representation of the different purification strategies used. 
4.2.1. CsCl purification 
Phage lysates particles were further purified and concentrated by means of 
ultracentrifugation (104,000 x g, 4 °C) for 3.5 h in a CsCl (PanReac AppliChem, 
Darmstadt, Germany) gradient with densities of 1.33 to 1.70 g/cm3 in a swigging 
bucket centrifuge as described by Lavigne et al. (2009). The resulting high-titer phage 
suspension (ca. 3 – 4 ml) was dialyzed with a Slide-A-lyzer Mini Dialysis device (10,000 
MWCO, Thermo Scientific, Hudson, NH) three times for 30 min at 4 °C against 1 l of 
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saline to remove residual CsCl. The CsCl-purified phage samples (φC) were stored at 
4 °C and the phage titer was determined on the following day. 
4.2.2. Two-phase extraction 
4.2.2.1. Organic solvent (OS) treatment: 1-octanol 
Phage φET and φCET preparations were treated with an organic solvent (1-octanol; 
Sigma-Aldrich, Munich, Germany), as described by Szermer-Olearnik and Boratyński 
(2015). Briefly, 500 µl of the phage preparation (either phage lysate (φET) or CsCl 
purified phages (φCET)) was transferred to a 1.7 ml Eppendorf tube. Subsequently, 
MgCl2 (Sigma-Aldrich) was added to a final concentration of 0.02 M. This mixture was 
incubated for 1 h at 4 °C. After incubation, 1-octanol (40 % v/v) was added and mixed 
overnight by inverting in a vertical rotator at room temperature. The mixture was 
incubated for 1 h at 4 °C prior to centrifugation at 4,000 x g for 10 min. The upper 1-
octanol phase was removed and the lower aqueous phase was transferred to Slide-A-
lyzer Mini Dialysis device (10,000 MWCO). Dialysis was performed against ethanol 
(25 %) for five subsequent rounds (one overnight incubation and four 2 h 
incubations). Subsequently, the samples were dialyzed against endotoxin-free saline 
for four rounds (one overnight and three incubations of two hours). The purified 
phage solution was stored overnight at 4 °C and the phage titer was determined on 
the following day. 
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4.2.2.2. Detergent treatment: Triton X-100 
The Triton X-100 removal of endotoxins is based on general protocols for the removal 
of endotoxins from protein preparations, as described by Petsch and Anspach (2000). 
Above the critical micelle concentration of some detergents, endotoxins are trapped 
in a micellar structure by non-polar interactions of the alkyl chains of lipid A and the 
detergent and are consequently separated from the water phase. 
Detergents of the Triton series show a miscibility gap in aqueous solution. Above a 
critical temperature, the so-called cloud point, micelles aggregate to droplets with 
very low water content, thus forming a new phase. Endotoxins remain in the 
detergent-rich phase. The cloud point of Triton X-114 is at 22 °C, which is 
advantageous when purifying proteins. It requires mixing of the endotoxin-containing 
protein solution in the cold (usually at 4 °C) and allows separation of the two phages 
at temperatures of 22 °C or above. In contrast, the cloud point for Triton X-100 is at 
75 °C, which is not acceptable for most proteins or phages, because high 
temperatures might lead to inactivation. In the classical protocols, Triton is removed 
by centrifugation. This has as downside that it is impossible to remove all the Triton 
present in the sample. Alternatively, Triton can be removed by using activated 
charcoal (Marcus and Prusky, 1987), which has as an additional advantage that it is 
not necessary to use a two-phase system, which makes it possible to use Triton X-100 
(which has, due to its higher cloud point, the advantage of being used at room 
temperature). 
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A total volume of 200 µl of the phage solution (i.e. φET or φCET) was transferred to a 
1.7 ml Eppendorf tube. To this solution 3 % (v/v) Triton X-100 (Sigma-Aldrich) was 
added and incubated for 30 min at room temperature while shaking at 750 rpm. After 
incubation, 12 % activated carbon (Sigma-Aldrich) was added to remove the Triton X-
100 (Marcus and Prusky, 1987). An additional 30 min of incubation was performed at 
room temperature while shaking at 750 rpm. The solution was centrifuged at 
maximum speed for 1 min, after which it was passed through a 0.45 µm membrane 
to remove residual activated carbon. All steps were repeated for an additional two 
rounds, i.e. a total of three Triton X-100 treatments. The purified phage solution was 
stored overnight at 4 °C and the phage titer was determined on the following day. 
4.2.3. Enzymatic inactivation of endotoxins: alkaline phosphatase (AP) 
The inactivation of endotoxins through enzymatic degradation by means of alkaline 
phosphatase was described by Bentala et al. (2002). Briefly, alkaline phosphatase 
(rSAP (1,000 U/ml;7.5 U/reaction of 300 µl), New England Biolabs, New England, MA) 
together with the CutSmart buffer (New England Biolabs; as described by the 
manufacturer) was added to the phage sample and incubated for 60 min at 37 °C. 
Subsequently the enzyme was inactivated by heating the solution for 5 min at 65 °C. 
Following endotoxin inactivation, the titer of the phage solution was determined. 
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4.2.4. Adsorption techniques 
4.2.4.1. Endotrap HD 
Endotrap HD is an affinity chromatography based strategy using bacteriophage-phage 
derived proteins that are fixed on the column matrix and bind endotoxins with a high 
affinity and specificity. According to the manufacturer, Endotrap HD is able to remove 
endotoxins from protein, peptides, antibodies, RNA/DNA, antigens and plant extract 
samples with an endotoxin removal efficiency of 99.99 %. It also is claimed to have a 
wide pH range (4 – 10) of activity and that high salt concentrations do not affect the 
endotoxin removal capacity.  
The phage lysates (φET) or CsCl purified phage lysates (φCET) were further purified 
from endotoxins using the commercially available kit Endotrap HD (Hyglos, Bernried 
am Starnberger Seen, Germany), according to the instructions of the manufacturer. 
Briefly, three ml of the phage preparations were transferred to a sterile 15 ml Falcon 
tube (Becton Dickinson) and CaCl2 (Sigma-Aldrich) was added to a final concentration 
of 0.001 M. Prior to the addition of the phages to the columns, the columns were 
activated by the addition of 3 ml regeneration buffer. The columns were drained out 
completely before repeating the addition of the regeneration buffer. Subsequently, 3 
ml of the equilibration buffer was added and the columns were drained out 
completely before a second wash with the equilibration buffer was performed. Finally, 
the phage samples were added to the column and the eluate was collected in a 
sterile 15 ml Falcon tube (Becton Dickinson). The columns were then regenerated by 
washing them twice with 3 ml regeneration buffer. The columns could then be used 
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for a second purification round or be stored by adding 1 ml of the storage buffer 
supplemented with 0.02 % sodium monoazide (Sigma-Aldrich). Following endotoxin 
removal, the titer of the phage solution was determined. 
4.2.4.2. Anion-exchange chromatography: Convective Interactive Media (CIM) 
disk 
Phage purification using monolithic anion-exchange chromatography with CIM DEAE 
disk columns (BIA Separations, Ljubljana, Slovania) was carried out, basically as 
described by Adriaenssens et al. (2012). Briefly, prior to phage purification, the 
complete chromatography set up (Äkta FPLC system (GE Healthcare, Little Chalfont, 
UK with a P900 pump system) was flushed with 1 M NaOH. The loading column was 
washed three times with endotoxin-free water. Next, approximately 10 ml of one of 
the high titer phage preparations was loaded onto the chromatography set up. Pump 
A contained Tris-HCl (20 mM, pH 7.5) buffer whereas pump B contained Tris-HCl (20 
mM, pH 7.5) with Na l (2 M) buffer. Prior to the elution of the phages from the CIM 
DEAE disk column, the column (containing the phages) was washed with the Tris-HCl 
(20 mM, pH 7.5) buffer. Elution of the phages from the CIM DEAE disk columns was 
achieved by washing with an increasing percentage of the Tris-HCl (20 mM, pH 7.5) 
with NaCl (2 M) buffer relative to the Tris-HCl (20 mM, pH 7.5) buffer.  
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4.3. Endotoxin quantification 
Quantification of the endotoxin concentrations in the differently treated phage 
preparations was performed using two different commercially available methods. 
Prior to the endotoxin determination, all phage samples were diluted using 
Endotoxin-Free Dulbecco’s PBS (Millipore, Darmstadt, Germany). 
The endotoxin removal efficacy of each purification approach was calculated by first 
determining the amount of endotoxins per plaque forming unit (pfu) by dividing the 
endotoxin concentration by the phage titer for each preparation (1). 
Normalised endotoxin content =
𝐸𝑈/𝑚𝑙
𝑝𝑓𝑢/𝑚𝑙
 (1) 
 Subsequently the normalized endotoxin content of each sample was determined by 
multiplying the endotoxins per pfu with the phage recovery (2), i.e. the phage titer of 
the purified preparation divided by original preparation.  
 
Phage recovery =  
(𝑝𝑓𝑢/𝑚𝑙)𝑝𝑢𝑟𝑖𝑓𝑖𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒
(𝑝𝑓𝑢/𝑚𝑙)𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑠𝑎𝑚𝑝𝑙𝑒
 (2) 
The endotoxin removal efficacy (2) was then calculated by dividing the normalized 
endotoxin concentration of the purified sample by the normalized endotoxin 
concentration of the original sample (i.e. φET or φCET) and subtracting this value 
from 1. 
Endotoxin removal efficacy = 1 − 
[(
𝐸𝑈/𝑚𝑙
𝑝𝑓𝑢/𝑚𝑙⁄ )×phage recovery]𝑝𝑢𝑟𝑖𝑓𝑖𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒
[(
𝐸𝑈/𝑚𝑙
𝑝𝑓𝑢/𝑚𝑙⁄ )×phage recovery]𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑠𝑎𝑚𝑝𝑙𝑒
  (3) 
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4.3.1. EndoZyme recombinant Factor C (rFC) Assay  
According to the manufacturer, EndoZyme (Hyglos, Bernried am Starnberger See, 
Germany) is an endpoint fluorescent microplate assay intended for in vitro 
quantitative determination of endotoxin (lipopolysaccharides, LPS) in 
pharmaceuticals and biological substances as well as for medical device testing using 
recombinant factor C (rFC). The enzymatically active rFC is activated by trace amounts 
of endotoxins. It is capable of binding both free and bound LPS/lipid A (the 
biologically potent moiety of LPS) with high affinity. Being at the initial step of the 
coagulation cascade, Factor C functions as a very sensitive and specific biosensor of 
endotoxins, capable of detecting pictogram to nanogram levels of endotoxins (Ding 
and Ho, 2010). Endozyme is able to reliably detect endotoxins within the range of 
0.005 to 50 EU/ml. The phage samples were diluted until their endotoxin 
concentration fell within this range. The assay was performed as described by the 
manufacturer. 
4.3.2. Endosafe-PTS 
According to the manufacturer, the Endosafe-PTS (Charles River, CA) is a rapid, point-
of-use test system that provides quantitative LAL results within 15 minutes. It is a 
miniaturized version of the LAL assay using rFC. It is able to detect endotoxins within 
the range of 0.005 to 10 EU/ml. The endotoxin determination was performed by the 
VIB Protein Service Facility (Ghent University) as described by the manufacturer. 
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Table 1: Different phages used in the different purification strategies. For each phage, taxonomical family and bacterial host strain are presented, as well as the titer of the phage lysates, 
before application of any endotoxin removal techniques. 
Bacteriophage name Phage family Bacterial Host Titer (pfu/ml) Reference Isolated by Isolation date 
P. aeruginosa phage PNM Podoviridae P. aeruginosa strain 573 1.8 x 10
13 
Merabishvili et al. (2009) N. Lashki & M. 
Tediashvili 
1999 
P. aeruginosa phage 
LUZ19 
Podoviridae P. aeruginosa strain 573 5.0 x 10
13 
Lammens et al. (2009) P.J. Ceyssens 2006 
P. aeruginosa phage GE-
vB_Pae-Kakheti25 
Siphoviridae P. aeruginosa strain 573 2.5 x 10
12 
Karumidze et al. (2012) N. Kvatadze 2012 
P. aeruginosa phage 14-1 Myoviridae P. aeruginosa strain 573 3.6 x 10
12 
Ceyssens et al. (2009) V. Krylov 2000 
S. aureus phage ISP Myoviridae S. aureus strain ATCC 
6538 
8.0 x 10
13 
Vandersteegen et al. (2011) Unknown 1920 - 1930 
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Table 2: Endotoxin removal efficacy. This is defined as the ratio of the endotoxin units (EU) per plaque forming unit (pfu) multiplied by the phage recovery of the purified sample and the 
original sample substracted from one. Negative values indicate an enrichment of endotoxins. N.D.: not determined. N.A.: not applicable. Dark gray indicates endotoxin removal efficiencies 
larger than 99%, whereas light gray indicates endotoxin removal efficiencies between 80 – 99 % and white indicates below 80. CsCl: CsCl density centrifugation, OS: organic solvent, TX: Triton 
X-100, AP: alkaline phosphatase, CIM DEAE: Convective Interactive Media. 
Phage name 
Lysate 
(φET) 
CsCl 
(φC) 
 CsCl 
(φCET) 
(φET)  (φCET)  (φET)  (φCET) (φET)  (φCET)  (φET) 
OS TX AP CIM DEAE 
P. aeruginosa phage 
PNM 
N.A. 99.42% 63.09% 
99.98% 23.40% 93.21% 56.38% -9.62% 17.17% 98.15% 
P. aeruginosa phage 
LUZ19 
N.A. 18.42% 83.29% 
99.68% -16.55% N.D. 83.92% 2.84% 20.09% 40.39% 
P. aeruginosa phage 
GE-vB_Pae-Kakheti25 
N.A. 99.68% 94.56% 
92.97% 63.36% 93.71% 96.95% -5.83% 22.14% N.D. 
P. aeruginosa phage 
14-1 
N.A. 69.33% 64.97% 
63.83% 63.29% 92.86% 99.69% -38.96% 7.25% N.D. 
S. aureus phage ISP N.A. N.A. N.A. N.A. N.A. N.A. N.A. N.A. N.A. N.D. 
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Table 3: Titers of single phage after each specific endotoxin removal strategy. All phage titers are expressed as pfu/ml or phage recovery percentage, the amount of phages remaining after 
the purification as compared to the original sample (phage lysate after Endotrap HD (φET) or CsCl purified phage followed by Endotrap HD purification (φCET), respectively). N.D.: not 
determined. Dark gray indicates phage recovery above 90 %, light gray between 20 – 90 % and white below 75 %. CsCl: CsCl density centrifugation, OS: organic solvent, TX: Triton X-100, AP: 
alkaline phosphatase, CIM DEAE: Convective Interactive Media. 
Phage name 
 
Lysate 
(φET) 
CsCl 
(φC) 
CsCl 
(φCET) 
φET φCET φET φCET φET φCET φET 
OS TX AP CIM 
 pfu/ml % 
P. aeruginosa phage 
PNM 
1.80E+13 3.300E+13 3.00E+13 2.06 0.0004 2.00 2.10 2.61 1.57 2.44 
P. aeruginosa phage 
LUZ19 
5.00E+13 5.00E+11 5.00E+11 34.00 0.0024 N.D. 14.00 0.02 6.00 0.62 
P. aeruginosa phage 
GE-vB_Pae-Kakheti25 
2.50E+12 9.00E+10 9.00E+10 3.20 130.00 17.20 52.22 16.40 8.89 N.D. 
P. aeruginosa phage 
14-1 
3.60E+12 5.00E+12 5.00E+12 26.11 31.00 1.11 1.80 9.44 30.60 N.D. 
S.aureus phage ISP 8.00E+13 3.00E+11 3.00E+11 0.03 10.00 0.07 22.80 0.005 0.53 N.D. 
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  Figure 1: Schematic representation of the different endotoxin strategies used, starting from different phage preparations. 
Phage lysates were obtained by the overlay-agar method. Part of this phage lysate was used either for (A) endotoxin removal 
using Endotrap HD (φET) or (B) further purified through CsCl density centrifugation followed by Endotrap HD (φCET). These 
preparations were further treated for the removal of endotoxins through different strategies: (OS) Organic solvent: 1-octanol; 
(TX) detergent treatment: Triton X-100; (AP) Enzymatic inactivation of endotoxins: alkaline phosphatase; or (CIM) anion-
exchange chromatography: CIM DEAE disk column (only performed on two phages). 
Phage lysate 
OS 
Organic solvent:  
1-octanol 
TX 
Detergent treatment: 
Triton X-100 
AP 
Enzymatic 
inactivation of 
endotoxins: 
Alkaline phosphatase 
OS 
Organic solvent:  
1-octanol 
TX 
Detergent treatment: 
Triton X-100 
AP 
Enzymatic 
inactivation of 
endotoxins: 
Alkaline phosphatase 
CIM 
Anion-exchange 
chromatography: 
CIM DEAE disk 
column 
CsCl purification (φC) 
Endotrap HD (φET) Endotrap HD (φCET) 
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Figure 2: Final endotoxin concentration (EU/ml) present after different purification strategies for four different P. 
aeruginosa phages, normalized against a phage therapeutic titer (i.e. 108 pfu/ml). φET: lysates after Endotrap HD, φC: 
CsCl purification, φCET: φC after Endotrap, OS: Organic Solvent, TX: Triton X-100, AP: Alkaline Phosphatase, CIM 
DEAE: Anion Exchange using CIM DEAE disks. 
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Highlights 
 The endotoxin removal efficacy is phage specific for the different tested strategies. 
 The endotoxin removal strategies affect phage infectivity to different degrees. 
 CsCl density centrifugation leads to the highest endotoxin removal efficacy of the 
tested endotoxin removal strategies, with a reduction up to 99 %. 
 Complete removal of endotoxins was not obtained, a minimum of 2.84 % could be 
removed, leaving a maximum of 7,000,000 EU/ml in the phage preparation. 
